Back to results
US 7,803,910 B2Granted
Soluble CD164 polypeptides
AssigneeMerck Serono SA
InventorsGabriela Saborio, Christine Power, Amanda Proudfoot
Life of this patent
Estimating the term…
Abstract
The present invention relates to sCD164 variants and therapeutic uses thereof, in particular for treating or preventing inflammatory or autoimmune disorders.
Claims8
An isolated sCD164 variant polypeptide selected from:
- (i) a polypeptide comprising SEQ ID NO:
- 16;
- (ii) a fusion protein comprising SEQ ID NO:
- 16 and a radioactive label, biotin, fluorescent label, cytotoxic agent or a polymer;
- or
- (iii) a polypeptide comprising SEQ ID NO:
- 16 and a signal sequence.
4 more elements
A composition comprising a pharmaceutically acceptable carrier and a sCD 164 variant polypeptide selected from:
- (i) a polypeptide comprising SEQ ID NO:
- 16;
- (ii) a fusion protein comprising SEQ ID NO:
- 16 and a radioactive label, biotin, fluorescent label, cytotoxic agent or a polymer;
- or
- (iii) a polypeptide comprising SEQ ID NO:
- 16 and a signal sequence.
4 more elements
Dependencies are inferred from the claim text.